Dwd Pharmaceuticals Limited - Due diligence report

A 360° intelligence report on Dwd Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distress si…

1967-05-08 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
View plans
DP Dwd Pharmaceuticals Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Dwd Pharmaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
82/100
Trust Score
Low Risk

Dwd Pharmaceuticals is assessed as Low Risk with a Trust Score of 82/100. Dwd Pharmaceuticals is an active public limited indian non-government company incorporated in 1967, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.

Report generated on 03 Jul 2026 from the latest processed filings. Dwd Pharmaceuticals Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Neutral

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
82/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
50/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (1.80 cr) · 4 satisfied (16.63 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Standard Chartered Bank3 48.0 cr
Hdfc Bank Limited1 48.0 cr
Others1 48.0 cr
Compliance Score: 50/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 3 court forum(s).
  • 1 auditor resignation(s) filed - latest: M A PAREKH & ASSOCIATES on 2024-05-28.
  • Delayed payments to MSME suppliers disclosed (1 disclosure(s)).
  • 14 active GST registration(s).
Legal cases on record (3)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SACHIN NAVINCHANDRA DOSHI 01234567 Director 01/04/2018 6 yrs Approved
MEETA SAMIR SHETH 01234567 Director 01/04/2018 6 yrs Approved
KAUSHIK MANIAR 01234567 Director 01/04/2018 6 yrs Approved
NIRAJ ANILKUMAR MEHTA 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
4 allotment(s) · 1 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: SACHIN NAVINCHANDRA DOSHI (Whole-time director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 59+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (50/100).
1 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 2.35 Lakh.
3 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence72/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment84/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 1.80 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
29 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
15 Jun 2023
Charge satisfied
Standard Chartered Bank
16 Feb 2023
Charge created
Hdfc Bank Limited - 1.80 cr
01 Apr 2021
Director ceased
SACHIN NAVINCHANDRA DOSHI
26 Mar 2021
Charge created
Standard Chartered Bank - 1.00 cr
18 Mar 2021
Charge satisfied
Standard Chartered Bank
05 Mar 2021
Charge satisfied
Others
30 Dec 2020
Director ceased
KAUSHIK MANIAR
Director ceased
NIRAJ ANILKUMAR MEHTA
31 Oct 2020
Director ceased
JASWANT JAGJIBANDAS MEHTA
16 Sep 2020
Charge satisfied
Standard Chartered Bank
04 Sep 2020
Director appointed
KAUSHIK MANIAR (Director)
Director appointed
NIRAJ ANILKUMAR MEHTA (Director)
27 Mar 2020
Securities allotted
599 Equity Shares - 5.99 Lakh raised
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
14 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Amn Life U24230MH2003PTC140663 Mumbai, Maharashtra, India
Ideal Detonators Private Limited U24292TG1989PTC010513 Secunderabad, Telangana, India
Class One Agro Biotech & Fertilizer Private Limited U24129PN2013PTC149228 Tasgaon, Maharashtra, India
Bakson'S Homoeopathic U74899DL1989PTC036300 New Delhi, Delhi, India
Enaltec U21001MH2006PTC160020 Thane, Maharashtra, India
Quadragen U24301KA2010PTC055162 Bangalore, Karnataka, India
Lubi Gel Limited U24290RJ2021PLC074116 Jodhpur, Rajasthan, India
Grouppharma U24239MH1980PLC022889 Thane, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Dwd Pharmaceuticals before audits and certifications: compliance score 50/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Dwd Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Dwd Pharmaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 82/100, distress signals and MSME payment-delay disclosures - know whether Dwd Pharmaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Dwd Pharmaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Dwd Pharmaceuticals an active company?

Dwd Pharmaceuticals has MCA status “Active” with a compliance score of 50/100 (Moderate).

Is Dwd Pharmaceuticals financially healthy?

Dwd Pharmaceuticals has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Dwd Pharmaceuticals?

Its overall Trust Score is 82/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Dwd Pharmaceuticals?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Dwd Pharmaceuticals have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 4 earlier charge(s) stand satisfied.

Is Dwd Pharmaceuticals up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 50/100 (Moderate).

Is it risky to lend to Dwd Pharmaceuticals?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.